My brokers are saying the placement in KSX was snapped up in 3 days and overs are being considered. Macquarie Private wealth are leading it.
I have read the posts relating to margin and believe KSX have a very healthy margin >150% factored into their model for global rollout. For now, margin is skinny as QC and production out of Israel is expensive but they already have partners in Taiwan and China who I am sure will be in the global roll out plans.
My broker told me that at a presentation he went to the company is hoping to get the Wheezeometer cost down to Au$35-45 with it being sold at approx $350 at point of sale. Healthy margin for all.
What has really excited the brokers is the revenue stream to flow out of the doctor/hospital use of the Wholter with an expected $15-25 residual ticking into the KSX coffers after every $125 assessment is done on patients suffering from asthma or sleep apnia. Apparently there are around 2,000/month and growing.
What Paul Eisen has done here is demonstrated how real his links to monster markets are and the people who I have spoken to in the industry are saying this company is on the verge of exploding onto the global markets assisted by a team that has done it all before.
DYOR.....I have, and know that this product suite will help people who suffer from asthma and the parents/carers and supporters of the people who suffer will finally have tools that can help them better understand and manage the conditions they have...."Peace of Mind" technology.
My chemist reckons the Wheezeometers will sell like hot cakes!!!!
KSX Price at posting:
5.0¢ Sentiment: Buy Disclosure: Held
